Skip to main content COVID-19: Asymptomatic

New Post Public Reply Private Reply Replies (0) Message Board
Crunch55
320
Skip to main content



COVID-19: Asymptomatic pharmacy staff to get at-home tests
by Valeria Fiore 11/11/2020 1 News
Asymptomatic NHS staff could verify whether they contracted the virus in under one hour. Pic credit: Innova Medical Group
Asymptomatic NHS staff could verify whether they contracted the virus in under one hour. Pic credit: Innova Medical Group

Asymptomatic NHS staff working in a community pharmacy in England will be able to test themselves for COVID-19 at home twice a week, NHSE&I has confirmed.
All “patient-facing” NHS staff will receive “appropriate training” that will enable them to use the lateral flow tests at home twice a week and get the results back before going to work.

The announcement was made by NHS England and NHS Improvement (NHSE&I) national medical director Professor Stephen Powis, national director for emergency and elective care Pauline Philip, and chief nursing officer Ruth May in a letter to NHS staff earlier this week (November 9).

An NHSE&I spokesperson confirmed to C+D today (November 11) that the lateral flow tests will be made available to “all staff working in community pharmacies”.

“Following further scientific validation of the lateral flow testing modality, and confirmation over the weekend from test and trace that they can now supply the NHS with sufficient test kits, we are pleased to confirm that asymptomatic testing will be made available to all patient-facing NHS staff,” Professor Powis, Ms May and Ms Philip said.

The lateral flow testing technology will be implemented by 34 trusts this week, and the NHS will work with NHS staff “to ensure that full rollout is in place from next week”, they added.

Lateral flow test
The NHS in England selected the Innova lateral flow device for wider rollout among NHS staff.

These come in boxes of 25, containing 25 cartridges, swabs and two bottles of buffer. Instructions on how to use these tests, along with a training video for trainers and a video for NHS staff will be “available shortly”, according to the NHS letter.

Professor Powis, Ms May and Ms Philip said in the letter that the new lateral flow tests “have a lower specificity and sensitivity” than reverse transcription-polymerase chain reaction (RT-qPCR) tests, but staff will be testing twice a week, which “helps mitigate the sensitivity considerations”.

“To mitigate the lower specificity, all positive results will be retested via PCR”, they added.

Speaking before the Health and Social Care Committee and Science and Technology Committee yesterday (November 10), NHS test and trace chair Baroness Dido Harding said that “the new testing technologies that are being rolled out in the NHS, both lateral flow and loop-mediated isothermal amplification, enable turnaround times in less than an hour, which will be hugely valuable for the NHS as they roll those out”.

Earlier this week, the Department of Health and Social Care announced that an initial batch of 600,000 lateral flow tests would be sent out to local public health leaders this week. The directors of public health will decide who will have priority access to the tests and how these will be carried out.



Coronavirus
Lateral Flow Test
73% of people would get their COVID-19 vaccination at a pharmacy11/11/2020 | NewsGPhC flags potential shortage of prescribing supervisors for trainees12/11/2020 | News
Related articles
73% of people would get their COVID-19 vaccination at a pharmacy
11/11/2020 | 2 | News

1 Comments
Do you welcome this announcement?
Kevin Western, Community pharmacist
Posted on Thu, 12/11/2020 - 14:53
We are supposed to get priority tests anyway... but its not exactly straight forward, how will we get these and when? I doubt it will be done in any way thats easy to use

Login or register to post comments

Download the C+D app today for free on your iOS or Android phone or tablet. Access the latest and most popular news.
Download app
SIGN UP FOR OUR NEWSLETTERS
C+D Daily Bulletin• C+D CPD Bulletin• C+D Saturday Review• C+D Careers Bulletin• C+D Briefing Newsletter
Sign up now
Facebook

Twitter

Linked-in

Instagram
OTHER C+D SITES
SUPPORT
ABOUT
SECURITY
Chemist+Druggist is a trading division of Informa intelligence, and operates as part of Informa Markets (UK) Ltd.
We use cookies to enhance your user experience. Click here to find out more.Accept
42
SHARES

Quantum Materials Corp. (QTMM) Stock Research Links

QTMM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cepheid's FDA Clearance Boosts Hemorrhagic Fever Test

Updated Category News Views 81

Quick Detection for Deadly Viruses In the world of diagnostics, speed isn't just a luxury; it's a lifeline. Cepheid’s latest move—getting the FDA’s nod for their Xpert Hemorrhagic Fever Panel Test—is a big deal. Why? Imagine being able to detect nasty viruses like Ebola, Marburg, Lassa, and Crimean-Congo hemorrhagic fever in just over an hour. That's what this...

Continue Reading
Icahn Faces $225M Q3 Loss, But CVR Deal Shines

Updated Category News Views 30

Icahn Enterprises Stumbles in Q3, Losses Widen When a company's financial report starts with a loss, it's like stepping into a bar fight expecting cheers—you’re bound to get more than you bargained for. Icahn Enterprises L.P.'s third quarter report isn't exactly a rosy picture. We're staring down the barrel of a net loss of $225 million, a sharp contrast to the $287...

Continue Reading
MINISO Prepares to Reveal September 2026 Results

Updated Category News Views 74

News flash, folks — MINISO Group, that quirky IP-driven retailer we all have an eye on, has set the stage for its next big reveal. Come November 17, 2026, they’re gonna lay down their financial cards for the September quarter. It’s prime time for any investor keen on dissecting their performance and plans for the future. What the Call Means for Stakeholders MINISO's...

Continue Reading
Differentia Bio's AI: Transforming Drug Development Dynamics

Updated Category News Views 51

The Future of Drug Development: AI's New Role When it comes to pharmaceutical R&D, Some outfits are playing pin the tail on the donkey, but Differentia Bio over here is sharpening the pin with some futuristic gadgetry. Yep, they're jazzing up the game with AI-powered digital twins, building lifelike disease environments that predict therapeutic outcomes with precision...

Continue Reading
ISU and Ares Forge Path in Solid-State Battery Tech

Updated Category News Views 57

Solid-State Dreams Meet AI Magic Ah, the sweet sound of synergy. ISU Specialty Chemical and Ares Materials are brewing up something that could shake the battery world—solid-state cells juiced by AI-driven polymer magic. Now, the tech and finance geeks are likely on the edge of their seats. This isn't just another run-of-the-mill collab; it's a heavyweight match to speed...

Continue Reading
Doximity Faces Class Action: Investor Guidance Needed

Updated Category News Views 37

Doximity Lands in Hot Water: The Stakes for Investors Alright, traders, there's a storm brewing around Doximity (NYSE:DOCS), and it's a doozy. A class action lawsuit has been slapped on this digital platform for medical pros, and the accusations are serious. If you rode the wave and snagged yourself some shares between August 8, 2024, and May 13, 2026, you're right in the...

Continue Reading
RepData's New Platform Redefines Market Research Game

Updated Category News Views 34

Ever look at your market research and think, 'Is this really the best we can do?' RepData just rolled up like they own the place with their Verified Intelligence Platform (VIP), promising to make those wild data quality doubts a thing of the past. RepData’s Game-Changer in Research RepData's stepping into the ring with their VIP, aiming to shake up the way research...

Continue Reading
Oracle's $20 Billion Offering: What Investors Need to Know

Updated Category News Views 118

Oracle's Big Play: A $20 Billion Offering Nobody said playing in the big leagues was easy, and Oracle seems to be doubling down on that idea. Today, they spilled the beans on their ambition to rake in a cool $20 billion through an offering of common stock and senior notes. For those of us who keep a close eye on NYSE:ORCL, this is more than just a number—it's a signal...

Continue Reading
PRIMA Invests £10M to Propel CC Forum's Global Reach

Updated Category News Views 98

Strategic Commitment for Global Impact You've got to hand it to these folks—they're on a mission to roll up their sleeves and tackle climate change head-on. Max Studennikoff, the brains behind CC Forum, just inked a Letter of Intent with Alexander Zhardanovsky, founder of PRIMA, punctuated by an eye-popping £10 million pledge. It's all about boosting the Forum’s...

Continue Reading
Handle Plumbing Emergencies Swiftly, Expert Advises

Updated Category News Views 49

Fast Response Crucial in Plumbing Crises It's like nature's way of testing your mettle: a sudden plumbing emergency can make any homeowner feel like they're in over their head. The trick lies in how fast you act, and let me tell you, speed is everything in these situations. If you’ve never stared down a burst pipe or felt your heart drop at an overflowing toilet,...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth and Trends in Nuclear Medicine

Updated Category News Views 326

Nuclear Medicine Market Trends and Growth Projections Nuclear medicine is becoming an essential part of modern healthcare systems, offering significant diagnostic and therapeutic benefits. Recent industry analysis shows that the nuclear medicine market, valued at US$ 5.2 billion in 2022, is projected to grow to an astounding US$ 11.4 billion by 2031. This growth...

Continue Reading
Bitcoin Resilience: Experts Forecast Continued Growth Amid Dip

Updated Category News Views 107

Experts Forecast Bitcoin's Continued Growth In recent discussions, cryptocurrency experts have expressed a common belief that Bitcoin's long-term trajectory remains robust despite current fluctuations. Bitcoin has faced challenges in the short term, but the overarching consensus suggests that its bull market is far from over. The Impact of Federal Reserve Policies...

Continue Reading
Iovance Investors Urged to Act Before the July 14 Deadline

Updated Category News Views 170

Important Notice for Iovance Investors Levi & Korsinsky, LLP is reaching out to investors of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) regarding a class action securities lawsuit. This notice serves to inform shareholders of the impending deadline for becoming a lead plaintiff, which is set for July 14, 2025. Class Action Overview The legal action aims to recover...

Continue Reading
Startek® South Africa Achieves Best Employer Brand Award

Updated Category News Views 256

Startek® South Africa Celebrates Employer Branding Success Startek®, a leader in global customer experience solutions, is making waves in the industry with its recent accolade at the South Africa Leadership Awards. Startek's South Africa operations received the prestigious Best Employer Brand Award for 2025, recognizing their exceptional approach to employee engagement...

Continue Reading
ESS Tech Launches Energy Center™ Product for Sustainable Energy

Updated Category News Views 220

ESS Tech Introduces Energy Center™ Product ESS Tech, Inc. (NYSE: GWH), a frontrunner in the field of long-duration energy storage systems, has proudly announced the commercial launch of its innovative Energy Center™ product. This milestone comes with the successful delivery of multiple systems to a prominent utility in Florida, along with the completion of...

Continue Reading